Global Blood Cancer Diagnostics Market Forecast to Hit USD 31.79 Billion by 2036

The global Blood Cancer Diagnostics Market is witnessing significant expansion as healthcare systems increasingly focus on early detection and precision medicine. Industry analysis indicates that the market was valued at USD 14.06 billion in 2025 and is projected to reach USD 15.28 billion in 2026, eventually expanding to approximately USD 31.79 billion by 2036, growing at a compound annual growth rate (CAGR) of 7.6% during the forecast period.

Get Access of Report Sample: https://www.factmr.com/connectus/sample?flag=S&rep_id=47

Rising Cancer Incidence and Early Detection Driving Market Growth

The increasing prevalence of blood cancers globally is a major factor fueling demand for advanced diagnostic solutions. Early detection plays a critical role in improving patient outcomes and survival rates, encouraging healthcare providers to adopt advanced diagnostic tools.

Key factors driving market growth include:

Rising incidence of blood cancers such as leukemia and lymphoma

Growing demand for early and accurate diagnosis

Advancements in molecular and genomic testing technologies

Increasing adoption of precision medicine approaches

Expanding healthcare infrastructure and diagnostic capabilities

Technological advancements such as NGS and liquid biopsy are significantly improving diagnostic accuracy and enabling personalized treatment strategies.

Molecular/NGS Segment Leads Technology Adoption

Based on technology, molecular diagnostics and NGS account for around 39% of the market share in 2026, driven by their ability to provide detailed genetic insights and support precision oncology.

These technologies enable clinicians to identify genetic mutations, monitor disease progression, and tailor treatment plans to individual patients.

Hospital Laboratories Dominate Testing Settings

In terms of testing settings, hospital laboratories hold approximately 52% of the market share, as they serve as primary centers for cancer diagnosis and treatment.

Other important settings include:

Reference laboratories

Point-of-care testing (POCT) facilities

Research and academic institutions

The growing investment in hospital infrastructure and diagnostic equipment is further supporting this segment.

Expanding Applications Across Blood Cancer Types

Blood cancer diagnostics are widely used across different types of hematological malignancies, including:

Leukemia diagnostics

Lymphoma diagnostics

Multiple myeloma diagnostics

Other blood cancers

Among these, leukemia diagnostics represent a major application area, driven by high incidence rates and the need for continuous disease monitoring.

Regional Outlook

Asia-Pacific and Europe are key growth regions in the blood cancer diagnostics market, supported by increasing healthcare investments and expanding diagnostic infrastructure.

Countries such as China, Germany, the United Kingdom, Japan, and India are witnessing strong growth. China is expected to grow at around 8.1% CAGR, while India is projected to grow at approximately 7.0% CAGR through 2036.

Government initiatives, healthcare modernization programs, and increasing access to diagnostic services are contributing to regional market expansion.

Competitive Landscape

The blood cancer diagnostics market is highly competitive, with several global companies focusing on innovation and advanced diagnostic technologies.

Key players include:

F. Hoffmann-La Roche Ltd.

Illumina Inc.

Thermo Fisher Scientific Inc.

QIAGEN N.V.

Becton, Dickinson and Company

Sysmex Corporation

Agilent Technologies Inc.

Bio-Rad Laboratories Inc.

Guardant Health Inc.

Natera Inc.

These companies are investing in genomic testing, liquid biopsy technologies, and AI-driven diagnostics to enhance accuracy and efficiency.

Future Outlook

The market is expected to evolve rapidly with the increasing adoption of precision medicine, liquid biopsy, and AI-based diagnostic tools. Innovations in multi-cancer blood tests and real-time disease monitoring are further transforming the landscape of cancer diagnostics.

As global healthcare systems continue to prioritize early detection and personalized treatment, blood cancer diagnostics will play a crucial role in improving patient outcomes and advancing oncology care worldwide.

Browse Full Report: https://www.factmr.com/report/47/blood-cancer-diagnostics-market

Purchase Full Report for Detailed Insights

For access to full forecasts, regional breakouts, company share analysis, and emerging trend assessments, you can purchase the complete report here: https://www.factmr.com/checkout/47

Have a specific Requirements and Need Assistant on Report Pricing or Limited Budget please contact us - sales@factmr.com

To View Related Report :

Blood Clot Retrieval Devices Market: https://www.factmr.com/report/blood-clot-retrieval-devices-market

Blood Sugar Tester Market: https://www.factmr.com/report/blood-sugar-tester-market

Blood Gas Analyzers Market: https://www.factmr.com/report/blood-gas-analyzers-market

Blood Based Biomarkers Market: https://www.factmr.com/report/blood-based-biomarkers-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.